Alumis (ALMS) Interest & Investment Income (2023 - 2024)

Alumis (ALMS) reported Interest & Investment Income of $2.0 million for Q2 2024, up 116.54% year-over-year from $913000.0 in Q3 2023, and up 116.54% on a QoQ basis from $913000.0 in Q2 2023.

Alumis (ALMS) has 2 years of Interest & Investment Income data on file, last reported at $2.0 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 7.90 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 114.80 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - 305,000.00
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 26.60 Mn
10 Alumis 1.84 Bn 1.75 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 1.98 Mn
Jun 30, 2023 913,000.00